<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMIODARONE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(a-mee'oh-da-rone)<br/><span class="topboxtradename">Cordarone, </span><span class="topboxtradename">Amio-Aqueous, </span><span class="topboxtradename">Pacerone<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic, class iii</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg tablets; 50 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Structurally related to thyroxine. Class III antiarrhythmic; also has antianginal and antiadrenergic properties. Totally unrelated
         to other antiarrhythmics. Acts directly on all cardiac tissues. Prolongs duration of action potential and refractory period
         without significantly affecting resting membrane potential.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>By direct action on smooth muscle, decreases peripheral resistance and increases coronary blood flow. Blocks effects of sympathetic
         stimulation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and treatment of life-threatening ventricular arrhythmias and supraventricular arrhythmias, particularly with
         atrial fibrillation.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of nonexertional angina, conversion of atrial fibrillation to normal sinus rhythm, paroxysmal supraventricular tachycardia,
         ventricular rate control due to accessory pathway conduction in pre-excited atrial arrhythmia, after defibrillation and epinephrine
         in cardiac arrest.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to amiodarone, or benzyl alcohol; cardiogenic shock, severe sinus bradycardia, advanced AV block unless a
         pacemaker is available, severe sinus-node dysfunction or sick sinus syndrome, bradycardia, congenital or acquired QR prolongation
         syndromes, or history of torsade de pointes; severe liver disease, children. Safety during pregnancy (category D) or lactation
         is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic disease, cirrhosis; Hashimoto's thyroiditis, goiter, thyrotoxicosis, or history of other thyroid dysfunction; CHF,
         left ventricular dysfunction; hypersensitivity to iodine; older adults; Fabry disease, especially with visual disturbances;
         electrolyte imbalance, hypokalemia, hypomagnesemia, hypovolemia; preexisting lung disease, COPD; open heart surgery.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO Loading Dose</span> 8001600 mg/d in 12 doses for 13 wk <span class="rdroute">PO Maintenance Dose</span> 400600 mg/d in 12 doses <span class="rdroute">IV Loading Dose</span> 150 mg over 10 min followed by 360 mg over next 6 h <span class="rdroute">IV Maintenance Dose</span> 540 mg over 18 h (0.5 mg/min), may continue at 0.5 mg/min <span class="rdroute">Convert IV to PO</span> Duration of infusion 3 wk use 400 mg PO<br/><span class="rdage">Child:</span> <span class="rdroute">PO Loading Dose</span> 1015 mg/kg/d or 600800 mg/1.73 m<sup>2</sup>/d, in 12 divided doses for 414 d cycle or until adequate control of arrhythmia <span class="rdroute">PO Maintenance Dose</span> 5 mg/kg/d or 200400 mg/1.73 m<sup>2</sup>/d once daily, may be able to reduce to 25 mg/kg/d 5 d per week<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Correct hypokalemia and hypomagnesemia prior to initiation of therapy.
            			
         </li>
</ul><span class="adminroutetype">Oral</span><br/><ul>
<li>Give consistently with respect to meals.</li>
<li>
            				Note: Only a physician experienced with the drug and treatment of life-threatening arrhythmias should give loading doses.
            			
         </li>
<li>
            				Note: GI symptoms commonly occur during high-dose therapy, especially with loading doses. Symptoms usually respond to dose reduction
            or divided dose given with food, including milk.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion: First rapid loading dose infusion:</span> Add 150 mg (3 mL) amiodarone to 100 mL D5W to yield 1.5 mg/mL.  <span class="methodtype">Second infusion during first 24 h (slow loading dose and maintenance infusion):</span> Add 900 mg (18 mL) amiodarone to 500 mL D5W to yield 1.8 mg/mL.  <span class="methodtype">Maintenance infusions after the first 24 h:</span>  Prepare concentrations of 16 mg/mL amiodarone. Note: (Use central line to give concentrations &gt;2 mg/mL).   
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Rapidly infuse initial 150 mg dose over the first 10 min at a rate of 15 mg/min. Over next 6 h, infuse 360 mg at a rate of
                  1 mg/min. Over the remaining 18 h, infuse 540 mg at a rate of 0.5 mg/min. After the first 24 h, infuse maintenance doses of
                  720 mg/24 h at a rate of 0.5 mg/min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Nitroprusside sodium,</b>
<b> sodium bicarbonate.</b>
<span class="incompattype"> Y-site:</span>
<b>Aminophylline, </b>
<b>ampicillin/sulbactam, </b>
<b>cefamandole, </b>
<b>cefazolin, </b>
<b>ceftazidime, </b>
<b>ceftizoxime, </b>
<b>ceftriaxone, </b>
<b>cefuroxime, </b>
<b>digoxin, </b>
<b>heparin, </b>
<b>imipenem/cilastatin, </b>
<b>magnesium sulfate, </b>
<b>piperacillin, </b>
<b>potassium phosphate,</b>
<b> sodium bicarbonate, </b>
<b>sodium phosphate.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) protected from light, unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Peripheral neuropathy (<span class="speceff-common">muscle weakness,</span> wasting numbness, tingling), <span class="speceff-common">fatigue,</span> abnormal gait, dyskinesias, <span class="speceff-common">dizziness,</span> paresthesia, headache. <span class="typehead">CV:</span> Bradycardia, <span class="speceff-common">hypotension</span> (IV), <span class="speceff-life">sinus arrest, cardiogenic shock</span>, CHF, arrhythmias; AV block. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Corneal microdeposits</span>, blurred vision, optic neuritis, optic neuropathy, permanent blindness, corneal degeneration, macular degeneration, photosensitivity. <span class="typehead">GI:</span>
<span class="speceff-common">Anorexia, nausea, vomiting, constipation,</span>
<span class="speceff-life">hepatotoxicity</span>. <span class="typehead">Metabolic:</span> Hyperthyroidism or hypothyroidism; may cause neonatal hypo- or hyperthyroidism if taken during pregnancy. <span class="typehead">Respiratory:</span> (Pulmonary toxicity) Alveolitis, pneumonitis (fever, dry cough, dyspnea), interstitial pulmonary fibrosis, <span class="speceff-both">fatal gasping syndrome</span> with IV in children. <span class="typehead">Skin:</span>  Slate-blue pigmentation, <span class="speceff-common">photosensitivity,</span> rash. <span class="typehead">Other:</span> With chronic use, angioedema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Significantly increases <b>digoxin</b> levels; enhances pharmacologic effects and toxicities of <b>disopyramide,</b>
<b>procainamide,</b>
<b>quinidine,</b>
<b>flecainide,</b>
<b>lidocaine, </b>
<b>lovastatin, </b>
<b>simvastatin;</b> anticoagulant effects of <span class="classification">oral anticoagulants</span> enhanced; <b>verapamil,</b>
<b>diltiazem,</b>
<span class="classification">beta-adrenergic blocking agents</span> may potentiate sinus bradycardia, sinus arrest, or AV block; may increase <b>phenytoin</b> levels 2- to 3-fold; <b>cholestyramine</b> may decrease amiodarone levels; <b>fentanyl</b> may cause bradycardia, hypotension, or decreased output; may increase <b>cyclosporine</b> levels and toxicity; <b>cimetidine</b> may increase amiodarone levels; <b>ritonavir</b> may increase risk of amiodarone toxicity, including cardiotoxicity. <span class="typehead">Herbal:</span>
<b>Echinacea</b> possible increase in hepatotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Approximately 50% absorbed (2286%). <span class="typehead">Onset:</span> 23 d to 13 wk. <span class="typehead">Peak:</span> 37 h. <span class="typehead">Distribution:</span> Concentrates in adipose tissue, lungs, kidneys, spleen; crosses placenta. <span class="typehead">Metabolism:</span> Extensively hepatically metabolized; undergoes some enterohepatic cycling. <span class="typehead">Elimination:</span> Excreted chiefly in bile and feces; also excreted in breast milk. <span class="typehead">Half-Life:</span> Biphasic, initial 2.510 d, terminal 4055 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP carefully during infusion and slow the infusion if significant hypotension occurs; bradycardia should be treated
            by slowing the infusion or discontinuing if necessary. Monitor heart rate and rhythm and BP until drug response has stabilized;
            report promptly symptomatic bradycardia. Sustained monitoring is essential because drug has an unusually long half-life.
         </li>
<li>Monitor for S&amp;S of: Adverse effects, particularly conduction disturbances and exacerbation of arrhythmias, in patients receiving
            concomitant antiarrhythmic therapy (reduce dosage of previous agent by 3050% several days after amiodarone therapy
            is started); drug-induced hypothyroidism or hyperthyroidism (see Appendix F), especially during early treatment period; pulmonary
            toxicity (progressive dyspnea, fatigue, cough, pleuritic pain, fever) throughout therapy.
         </li>
<li>Lab tests: Baseline and periodic assessments should be made of liver, lung, thyroid, neurologic, and GI function. Drug may
            cause thyroid function test abnormalities in the absence of thyroid function impairment.
         </li>
<li>Monitor for elevations of AST and ALT. If elevations persist or if they are 23 times above normal baseline readings,
            reduce dosage or withdraw drug promptly to prevent hepatotoxicity and liver damage.
         </li>
<li>Auscultate chest periodically or when patient complains of respiratory symptoms. Check for diminished breath sounds, rales,
            pleuritic friction rub; observe breathing pattern. Drug-induced pulmonary function problems must be distinguished from CHF
            or pneumonia. Keep physician informed.
         </li>
<li>Anticipate possible CNS symptoms within a week after amiodarone therapy begins. Proximal muscle weakness, a common side effect,
            intensified by tremors presents a great hazard to the ambulating patient. Assess severity of symptoms. Supervision of ambulation
            may be indicated.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Check pulse daily once stabilized, or as prescribed. Report a pulse 
         </li><li>Take oral drug consistently with respect to meals.</li>
<li>Become familiar with potential adverse reactions and report those that are bothersome to the physician.</li>
<li>Use dark glasses to ease photophobia; some patients may not be able to go outdoors in the daytime even with such protection.</li>
<li>Follow recommendation for regular ophthalmic exams, including funduscopy and slit-lamp exam.</li>
<li>Wear protective clothing and a barrier-type sunscreen that physically blocks penetration of skin by ultraviolet light (e.g.,
            titanium oxide or zinc formulations) to prevent a photosensitivity reaction (erythema, pruritus); avoid exposure to sun and
            sunlamps.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>